ログイン
言語:

WEKO3

  • トップ
  • ランキング
To

Field does not validate

To

Field does not validate

To
lat lon distance


インデックスリンク

インデックスツリー

  • RootNode

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 0 資料タイプ別
  2. 02 学位論文
  1. 250 大学院医歯学総合研究科(医)
  2. 60 博士学位論文
  3. 10 博士学位論文

Serum Anti-interferon-γ Autoantibody Titer as a Potential Biomarker of Disseminated Non-tuberculous Mycobacterial Infection

http://hdl.handle.net/10191/00051957
http://hdl.handle.net/10191/00051957
3d75d581-d7f3-49c6-b2ba-af5a6debb4f2
名前 / ファイル ライセンス アクション
r2nmk966.pdf 本文 (586.3 kB)
r2nmk966_a.pdf 要旨 (452.9 kB)
Item type 学位論文 / Thesis or Dissertation(1)
公開日 2020-11-12
タイトル
タイトル Serum Anti-interferon-γ Autoantibody Titer as a Potential Biomarker of Disseminated Non-tuberculous Mycobacterial Infection
言語
言語 eng
キーワード
主題Scheme Other
主題 Disseminated NTM
キーワード
主題Scheme Other
主題 neutralizing capacity
キーワード
主題Scheme Other
主題 biomarker
キーワード
主題Scheme Other
主題 serum interferon-γ autoantibody titer
資源タイプ
資源 http://purl.org/coar/resource_type/c_46ec
タイプ thesis
その他のタイトル
その他のタイトル 播種性非結核性抗酸菌症における抗インターフェロンγ自己抗体のバイオマーカーとしての役割
著者 Yoshizawa, Kazutaka

× Yoshizawa, Kazutaka

WEKO 178220

Yoshizawa, Kazutaka

Search repository
著者別名
識別子Scheme WEKO
識別子 178221
姓名 吉澤, 和孝
抄録
内容記述タイプ Abstract
内容記述 Purpose In the past decade, the relationship between naturally occurring interferon-γ-neutralizing autoantibodies (IFNγ-Ab) and disseminated non-tuberculous mycobacteria (NTM) infection has been established. Furthermore, immune suppressive therapy aimed at the suppression of antibody production has shown efficacy as a supportive treatment. However, the nature of antibody behavior and antibody titer during the course of this disease, as well as the pathophysiological significance of IFNγ-Ab, has not yet been fully elucidated. Methods Thirteen Japanese subjects suffering from disseminated NTM (dNTM) infection with IFNγ-Ab were evaluated. The fluctuation of IFNγ-Ab titer and the neutralizing capacity against IFN-γ during the course of the disease were retrospectively analyzed. IFNγ-Ab titers in the sera were quantified using an enzyme-linked immunosorbent assay; neutralizing capacity was evaluated via flow cytometry. Results Serum antibody titers were not constant during the treatment period and varied over the course of the disease. The antibody titer decreased when the disease was improved by anti-mycobacterial treatment (p < 0.01) and increased as the disease progressed (p < 0.05). Even after the antibody titer decreased, the neutralizing capacity against IFN-γ was maintained by individual sera. Conclusions Despite the improvement in the pathological condition via treatment, the patients’ sera maintained neutralizing capacity against IFN-γ. Antibody titer fluctuated over the course of the disease and exhibited potential as a biomarker for judgment of the disease state.
内容記述
内容記述タイプ Other
内容記述 Journal of Clinical Immunology. 2020, 40, 399–405.
DOI
識別子タイプ DOI
関連識別子 info:doi/10.1007/s10875-020-00762-1
権利
権利情報 【○!C】 Springer Science+Business Media, LLC, part of Springer Nature 2020
著者版フラグ
値 ETD
学位名
学位名 博士(医学)
学位授与機関
学位授与機関名 新潟大学
学位授与年月日
学位授与年月日 2020-09-23
学位授与番号
学位授与番号 13101甲第4796号
学位記番号
内容記述タイプ Other
内容記述 新大院博(医)甲第966号
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 07:50:15.053958
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3